Coriell supports biomarker discovery through multi-omics integration, combining genomics, transcriptomics, proteomics, and epigenomics to provide a comprehensive view of disease biology, therapeutic response, and patient stratification. This multi-omic approach allows researchers to capture biological complexity across multiple molecular layers, revealing connections that might be missed when analyzing a single data type alone.
Multiomics is increasingly critical in precision medicine, as it helps identify biomarkers that are more accurate, predictive, and clinically actionable. By capturing the full molecular context of a disease or treatment response, multiomics enhances the ability to uncover novel targets, stratify patients, and tailor therapeutic interventions.
Coriell’s advanced bioinformatics pipelines and consultative approach allow clients to extract meaningful insights from well-characterized clinical trial samples.
We assist with:
By combining high-quality biospecimens with advanced laboratory assays and analytical rigor, Coriell enables the discovery of diagnostic, prognostic, and therapeutic biomarkers that can accelerate drug development and support precision medicine initiatives.
Coriell’s biomarker programs have contributed to NIH research networks, pharmaceutical trials, and population-based studies. Our ability to integrate validated samples, multi-omic data, and regulatory-grade analytics makes us a trusted partner in translating biological insights into clinical breakthroughs. With decades of translational science experience, Coriell delivers a biomarker discovery platform that is as rigorous as it is innovative, ensuring your data is robust, reproducible, and ready for impact.
